R
Rocío González-Grande
Researcher at University of Málaga
Publications - 22
Citations - 1715
Rocío González-Grande is an academic researcher from University of Málaga. The author has contributed to research in topics: Liver transplantation & Hepatitis C. The author has an hindex of 12, co-authored 19 publications receiving 1325 citations. Previous affiliations of Rocío González-Grande include Victoria University, Australia.
Papers
More filters
Journal ArticleDOI
Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period
Raúl J. Andrade,M. Isabel Lucena,M. Carmen Fernández,G. Pelaez,Ketevan Pachkoria,Elena García-Ruiz,B. García-Muñoz,Rocío González-Grande,Angeles Pizarro,José Antonio Durán,Manuel Jimenez,Luis Rodrigo,Manuel Romero-Gómez,J.M. Navarro,Ramon Planas,Joan Costa,Africa Borras,Aina Soler,Javier Salmerón,Rafael Martín-Vivaldi +19 more
TL;DR: Patients with drug-induced hepatocellular jaundice have 11.7% chance of progressing to death or transplantation, and amoxicillin-clavulanate stands out as the most common drug related to DILI.
Journal ArticleDOI
Epidemiological Pattern, Incidence and Outcomes of COVID-19 in Liver Transplant Patients
Jordi Colmenero,Manuel Rodríguez-Perálvarez,Magdalena Salcedo,Magdalena Salcedo,Ana Arias-Milla,Alejandro Muñoz-Serrano,Javier Graus,Javier Nuño,Mikel Gastaca,Javier Bustamante-Schneider,Alba Cachero,Laura Lladó,Aranzazu Caballero,Aranzazu Caballero,Ainhoa Fernández-Yunquera,Ainhoa Fernández-Yunquera,Carmelo Loinaz,Inmaculada Fernández,Constantino Fondevila,Miquel Navasa,Mercedes Iñarrairaegui,Mercedes Iñarrairaegui,Lluís Castells,Lluís Castells,Sonia Pascual,Pablo Ramírez,Carmen Vinaixa,Carmen Vinaixa,M.L. González-Diéguez,Rocío González-Grande,Loreto Hierro,F. Nogueras,Alejandra Otero,J.M. Álamo,Gerardo Blanco-Fernández,Emilio Fábrega,Fernando García-Pajares,José Luis Montero,Santiago Tomé,Gloria de la Rosa,José Antonio Pons +40 more
TL;DR: Being chronically immunosuppressed, liver transplant patients have an increased risk of acquiring Covid-19 but their mortality rates are lower than matched general population, and complete immunOSuppression withdrawal should be discouraged.
Journal ArticleDOI
New approaches in the treatment of hepatitis C
TL;DR: The recent, accelerated incorporation since 2013 of new more effective DAA, with pan-genomic properties and excellent tolerance, has created a new scenario: shorter therapies, less toxicity and regimens free of PEG/RBV, which has enabled their almost generalised applicability in all patients.
Journal ArticleDOI
Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids.
Mercedes Robles-Díaz,Mercedes Robles-Díaz,A. González-Jiménez,Inmaculada Medina-Caliz,Camilla Stephens,Camilla Stephens,Miren García-Cortés,Miren García-Cortés,B. García-Muñoz,Aida Ortega-Alonso,E. Blanco‐Reina,Rocío González-Grande,Miguel Jiménez-Pérez,P. Rendón,J.M. Navarro,Pere Ginès,Martín Prieto,M. García-Eliz,Fernando Bessone,J.R. Brahm,Raymundo Paraná,María Isabel Lucena,María Isabel Lucena,Raúl J. Andrade,Raúl J. Andrade +24 more
TL;DR: An increase in hepatotoxicity (DILI) reporting related to the use of anabolic androgenic steroids (AAS) for bodybuilding is observed.
Journal ArticleDOI
Causality assessment in drug-induced hepatotoxicity
TL;DR: The use of diagnostic algorithms may add consistency to the diagnostic process either by translating the suspicion into a quantitative score or by providing a framework that emphasises the features that merit attention in cases of suspected hepatic adverse reactions.